Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis

Rheumatology

Volumn 46, Issue 7, 2007, Pages 1148-1152

  Walsh, Ceara A E ^a   Minnock, P ^b   Slattery, C ^a   Kennedy, N ^b   Pang, F ^c   Veale, D J ^a,b   Bresnihan, B ^a,b   FitzGerald, O ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b Rheumatology Rehabilitation   (Ireland)

^c ABBOTT LABORATORIES   (United Kingdom)

Author keywords

Adalimumab; Economic analysis; Infliximab; Quality of life; Therapeutic switch

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COST BENEFIT ANALYSIS; COST CONTROL; DISEASE ACTIVITY; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEALTH ECONOMICS; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OPEN STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DRUG COSTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PATIENT CARE; QUALITY OF LIFE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447307138     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem074     Document Type: Article

References (25)

1. Bansback N, Brennan A, Anis AH. A pharmacokinetic review of adalimumab in the treatment of rheumatic arthritis. Expert Rev Pharmacoeconomics Res 2005;5:519-29.
2. Haraoui B. Differentiating the efficacy of tumor necrosis factor inhibitors. J Rheumatol 2005;74(Suppl):3-7.
3. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumor necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl 2):iL13-6.
4. Villeneuve E, Haraoui B. Switching between TNF-alpha inhibitors in the treatment of rheumatoid arthritis. Int J Adv Rheumatol 2006;4:2-8.
5. Weaver AL. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2004;43(Suppl 3):iIi17-23.
6. Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B. The efficacy of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005;23:795-800.
7. Haraoui B, Keystone EC, Thorne JC et al. Clinical outcomes of patents with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004;31:2356-9.
8. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: Findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36.
9. Nikas SN, Voulgari PV, Alamanos Y et al. Efficacy and safety of switching from infliximab to adalimumab: A comparative controlled study. Ann Rheum Dis 2006;65:257-60.
10. van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis 2003;62:1195-8.
11. Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF. Adalimumab (Humira) restores clinical response in patients with secondary loss from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scan J Rheumatol 2005;34:353-8.
12. Nuijten MJ, Engelfriet P, Duijn K et al. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 2001;19:1051-64.
13. Schwartzman S, Morgan GJ Jr. Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res Ther 2004;6(Suppl 2):S19-S23.
14. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity score that includes twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
15. Cooper NJ. Economic burden of rheumatoid arthritis: A systematic review. Rheumatology 2000;39:28-33.
16. McIntosh E. Clinical audit. The cost of rheumatoid arthritis. Br J Rheumatol 1996;35:781-90.
17. Bansback NJ, Regier DA, Ara R et al. An overview of economic evaluations for drugs used in rheumatoid arthritis: Focus on tumor necrosis factor-alpha antagonists. Drugs 2005;65:473-96.
18. National Institute for Clinical Excellence. Technology Appraisal Guidance - No.36. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. London. 2002.
19. Bennett AN, Paterson P, Zain A, Grumley J, Panayi G, Kirkham B. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology 2005;44:1026-31.
20. Brocq O, Plubel Y, Breuil V et al. Etanercept - infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNF alpha. Presse Med 2002;31:1836-9.
21. van der Bijl AE, Breedveld FC, Antoni CE et al. Adalimumab (Humira) is effective in treating patients with rheumatoid arthritis who previously failed infliximab treatment [abstract SAT0062]. Ann Rheum Dis 2005;64(Suppl III):428.
22. Bombardieri S, McKenna F, Drosos AA et al. Efficacy and safety of adalimumab (HUMIRA®) in 899 patients with rheumatoid arthritis (ra) who previously failed etanercept and/or infliximab in clinical practice. Ann Rheum Dis 2006;65(Suppl II):178, Abstract THU0205.
23. Brocq O, Albert C, Roux C, Gerard D, Breuil V, Ziegler LE. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients. Joint Bone Spine 2004;71:601-3.
24. Hutchinson D, Tier J, Soper S, Wilson G, Davis M. The conversion of infliximab to adalimumab in stable RA patients [abstract 136]. Rheumatology 2005:44(Suppl 1):i72.
25. Fransen J, van Riel PLCM. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 2005;23(Suppl 39):S93-9.